Kaplan Fox Advises PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors to Act Before the Lead Plaintiff Deadline on September 22, 2026

Bleichmar Fonti & Auld LLP says a securities fraud class action has been filed against PROCEPT BioRobotics (NASDAQ:PRCT) and executives after an alleged discount program that incentivized bulk handpiece orders, potentially inflating revenue. The suit cites an 18% stock drop in Feb 2026 and earlier declines tied to Q2 2025, Q3 2025, and Q4 2025 results.

Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.

Dell Federal Systems LP lost a legal bid to dismiss a challenge to its $11.4 billion US Navy contract. The US Court of Federal Claims ruled Dell did not prove Minburn Technology Group's claim lacked merit. The contract involves cloud subscriptions and Microsoft products. Judge Loren A. Smith denied Dell's motion to dismiss.

Meta (META) is facing a trial in California, with states seeking up to $1.4 trillion in penalties and changes to Facebook and Instagram. The states allege Meta's business model harms users, while Meta argues it enforces age limits. A judge will decide the case, with a ruling expected in October. Meta previously lost a similar case in New Mexico, facing a $942 million fine.